Medicsen
Needle-free drug delivery platform based on sonophoresis (ultrasounds) to replace needles and cannulas in the transdermal delivery of large molecules.
- biotechnology
- horizon europe
- sustainable development goals
- dt and ls
- woman founder
- spinout
- immersive technologies
- eit ecosystem
- wearable
- diabetes
- eit health
- digital care
- patient care
- personal health
- non-invasive medical devices and treatments
- eit supernovas
- seal of excellence ec
- eicfund
- chronic disease
- bootcamps (eit health)
- investor network (eit health)
- mentoring and coaching network (eit health)
- investor network 2019 (eit health)
- mentoring and coaching network 2019 (eit health)
- bootcamp 2019 (eit health)
- bridgehead europe (eit health)
- drug delivery systems
- bridgehead europe 2018 (eit health)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | €5.0m | Grant | |
| Total Funding | 000k | ||
| EUR | 2018 |
|---|---|
| Revenues | 0000 |
| EBITDA | 0000 |
| Profit | 0000 |
| EV | 0000 |
| EV / revenue | 00.0x |
| EV / EBITDA | 00.0x |
| R&D budget | 0000 |
Source: Company filings or news article
Related Content
We have developed a sonophoresis-powered SMARTPATCH drug
delivery platform - a needle and cannula-free, wearable technology that harnesses the power of ultrasound to provide a safe, controlled, and painless method for delivering large molecule medicines, starting initially on insulin.
Building upon seven years research, the platform utilises ground-breaking sonophoresis ultrasound technology to naturally enlarge skin pores, facilitating the painless administration of medications. Whilst many organisations have looked at transdermal sonophoresis drug delivery, we are the only company that has managed to create a miniaturized sonophoresis device, small enough to be wearable and suitable to deliver several large molecules with rapid adaptation.
We demonstrated feasibility to TRL5 (proven safe and effective delivery of insulin in vivo), won over 50 European innovation awards, and secured high-profile Pharma/Medtech partners as Merck, pilots with different stakeholders and their molecules of interest, and LOIs from BIOTON or LTS Lohmann stating their interest to validate the technology on human trials.